Amoéba

Legal Proceedings Report • Oct 19, 2022

PRESS RELEASE

Amoeba withdraws its biocide file in Canada to focus its resources on strategic priorities

Lyon (France), October 19, 2022 - 17h45 - AMOÉBA (FR0011051598 - ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in development phase, announces that it will not pursue the application for its living amoeba-based biocide in Canada.

Considering the high regulatory risk of this application, which mobilizes human and financial resources, Amoeba has decided to definitively withdraw the application for registration in Canada and to focus its resources on low regulatory risk applications, mainly the biocontrol application which has received positive evaluations in Europe and in the United States so far (see Press Releases of April 25, 2022 and September 29, 2022 respectively) and the biocidal application in closed cooling towers in the United States (see Press Release of August 10, 2022).

Amoeba is also pursuing its research and development of other uses of the amoeba, in its non-living lysed form, which presents a much lower regulatory risk than the living form, and therefore a high chance of success.

About Amoéba :

Founded in 2010, Amoéba is a French company, based in Chassieu (Lyon, France), specialised in the treatment of microbiological risk in natural resources. Over the last ten years, Amoéba has developed a triple scientific, industrial and commercial expertise around the amoeba Willaertia magna C2c Maky. This biological solution is an alternative to the chemical products widely used today. Amoéba is currently focusing on the biocontrol market for plant protection, estimated at €1.6 billion (1), as well as on the US market for industrial water treatment in closed circuits. In the long term, the Company plans to develop new applications such as the treatment of chronic wounds, valued at €751 million (2) in the United States. The commercialisation of crop protection, biocides and healthcare products is subject to local regulatory approvals. The company is currently testing the biocontrol application for plant protection and does not market any products.

Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. More information on www.amoeba-nature.com.

1. marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016.

2.Amoéba data

Contacts:

Amoéba Valérie FILIATRE Deputy General Manager +33 4 26 69 16 00 v.filiatre@amoeba-nature.com Calyptus Investor & Press Relations Nicolas HELIN / Mathieu CALLEUX +33 1 53 65 37 90 /91 amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2022 under number D22-0280 and available on the AMOÉBA website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forwardlooking statements.